Leads development and execution of multi-year global medical strategy for the nephrology indications and LCM of TAK-279 (mezagtiamab) and other pipeline assets, appropriately aligned with overall assets strategy and GPT, incorporating various functional strategies across functions in R&D and Global Portfolio Division (Clinical, Medical, Regulatory, Global Evidence and Outcome (GEO), PV, Global Product Launch Strategy (GPLS), Marketing and Commercial Excellence (MCE), and the countries/LOCs). Serves as the global scientific expert within Takeda in support of nephrology indications and LCM of mezagtiamab and other pipeline assets. Leads the Medical Strategy Team (MST) for the nephrology indications of mezagtiamab and other pipeline assets. Responsible for development execution of Global Medical plans and collaboration with the counties/LOCs as appropriate. Develop and manage the Global Medical budget for nephrology TA. Acts as a senior company representative interacting with external scientific leaders, patient advocacy groups and/or regulatory authorities. Establishes appropriate strategic partnerships with nephrology centers of excellence, patient organizations, and expert HCPs. Collaborates with Legal, Ethics, Compliance and Regulatory functions to ensure appropriate interactions between Global Medical personnel and external stakeholders.

By applying, you consent to your information being transmitted by Jobrapido to the Employer, as data controller, through the Employer’s data processor SonicJobs.
See Takeda Pharmaceutical Terms of Use at https://www.takeda.com/terms-of-use/ and Privacy Policy at https://www.takeda.com/privacy-notice/ and SonicJobs Privacy Policy at https://www.sonicjobs.com/us/privacy-policy and Terms of Use at https://www.sonicjobs.com/us/terms-conditions